China’s biotechnology sector is on track for another record year in licensing activity as global pharmaceutical companies intensify their search for innovative drug candidates to offset looming patent expirations and rising research costs. Data from industry tracker Pharmcube shows that out licensing deals
China could become one of the first countries globally to approve a drug entirely designed by artificial intelligence, signalling a major shift in how new medicines are discovered and developed. Pharmaceutical executives say advances in AI and human genetics are accelerating China’s transition
China’s cell therapy sector is drawing renewed investor interest as NewCure Biotech raised more than 200 million yuan, or about $28 million, in a Series B financing round to accelerate development of its TCR T pipeline targeting solid tumors. The round was co
A milestone moment for AI driven drug development China’s biotech sector has reached a landmark moment as Hangzhou based start-up MindRank advanced its weight loss drug into Phase 3 clinical trials. The development marks the first time a Category 1 new drug in
Funding in genomics and personalized medicine has become a key driver of innovation in China’s biotech sector. With the increasing application of genetic sequencing, precision therapeutics, and data-driven healthcare, financial support is crucial for research, development, and commercialization. Investment flows from government programs,
CRISPR-Cas9 technology has revolutionized genetic research, enabling precise editing of DNA sequences in living organisms. Chinese biotech labs have emerged as leaders in CRISPR applications, advancing research in disease treatment, agriculture, and therapeutic innovation. While CRISPR offers immense potential, it raises ethical questions
China’s biotech sector is making significant strides in addressing rare diseases through research, innovation, and advanced laboratory techniques. Rare diseases, often genetic in origin, affect a small percentage of the population but present complex challenges for diagnosis, treatment, and drug development. Chinese biotech
